Search the Newsreel

Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight

Arrowhead Pharmaceuticals (ARWR) recently reported Q3 2026 results with sales of US$75.25 million and a net loss of US$194.28 million, attracting renewed investor attention. While the stock trades close to a common fair value estimate of $89.08, a discounted cash flow model suggests a …

ARWR Rallies 7% This Week As Europe Edges Closer To Redemplo Approval Amid Analyst Optimism

Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Assenagon Asset Management S.A. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 243.8% in the second quarter, bringing its total holdings to 201,927 shares valued at $16.5 million. This move is part of a broader trend where institutional investors now own 62.61% …

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Arrowhead Pharmaceuticals (ARWR) reported a significant increase in Q3 2026 sales but also saw its net loss widen considerably. Despite generating over US$400 million in year-to-date sales, rising expenses and reduced collaboration revenue are impacting profitability, making the success of their late-stage programs like …

Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Pacer Advisors Inc. has invested $1.50 million in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by purchasing 23,922 shares in the first quarter. Institutional investors now own 62.61% of the company. Despite reporting a quarterly revenue beat, Arrowhead Pharmaceuticals missed EPS expectations, leading to some reduced future EPS …

FY2026 Earnings Estimate for ARWR Issued By HC Wainwright

Zacks Research Analysts Increase Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received an average recommendation of "Moderate Buy" from thirteen brokerages, with an average 12-month price target of $97.33. Analysts have mixed outlooks, with some raising price targets and long-term EPS forecasts, while others cut near-term earnings estimates, reflecting expected …

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress

Arrowhead Pharmaceuticals (ARWR) stock dropped 3% after reporting a widening net loss of US$194.3m in Q3 2026, despite increased revenue and positive Phase III trial results for plozasiran. The market reacted to the deepening losses, while long-term investors are likely weighing the R&D spend …

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside

Arrowhead Pharmaceuticals, Inc. (ARWR) has seen its average 12-month price target raised from $107.6 to $110.2 by 10 analysts, suggesting a 23% potential upside from its August 4th closing price. The consensus rating for the stock remains a "Buy" among 14 covering analysts, with …

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Acquires PRV to Accelerate sNDA Process for Plozasiran in sHTG On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced it signed an asset purchase agreement with an undisclosed party …

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Arrowhead Pharmaceuticals has acquired an FDA Rare Pediatric Disease Priority Review Voucher to accelerate the review process for its upcoming Supplemental New Drug Application (sNDA) for plozasiran. This sNDA aims to expand the approved indication of plozasiran, currently marketed as REDEMPLO, to include patients …

FDA voucher could put Arrowhead's planned drug filing on a six-month review track

Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this voucher to expedite the FDA review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at treating severe hypertriglyceridemia (sHTG), …

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), leading to plans for a supplemental New Drug Application. The company also highlighted continued growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS), with prescription volumes more than doubling. Despite …

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals announced its fiscal 2026 third-quarter results, highlighting significant progress in its commercial product REDEMPLO and its robust R&D pipeline. Key achievements include the strong momentum of REDEMPLO's U.S. launch and new marketing authorizations in Europe and Australia, positive topline results for plozasiran …

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 3, 2026

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its Board of Directors approved inducement grants for 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, fall under NASDAQ Listing Rule 5635(c)(4) and are separate from stockholder-approved equity incentive plans, …

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Arrowhead Pharmaceuticals announced positive Phase 3 results for plozasiran in severe hypertriglyceridemia and completed enrollment for the zodasiran Phase 3 trial. These developments bolster the company's cardiometabolic RNAi pipeline, potentially diversifying future revenue and broadening treatment options for lipid disorders. The strong clinical data …

Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake

Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 6,384,903 shares in Arrowhead Pharmaceuticals Inc. (ARWR), representing a 4.53% stake in the company. This disclosure, filed as a SCHEDULE 13G/A, indicates that Vanguard Portfolio Management has sole voting power …

B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123

B. Riley Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and increased the price target to $123. This adjustment reflects the firm's continued confidence in the company's financial prospects and market position.

Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress

Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk …

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones

Arrowhead Pharmaceuticals recently reported that its siRNA drug plozasiran met all primary and key secondary endpoints in two global Phase 3 trials for severe hypertriglyceridemia, while also completing patient enrollment for the YOSEMITE Phase 3 trial of zodasiran in the ultra-rare condition homozygous familial …

Equities Analysts Set Expectations for ARWR FY2027 Earnings

Arrowhead Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Arrowhead Pharmaceuticals (ARWR) had 801 employees worldwide as of March 2026, marking a 51.4% growth since 2023. The company is actively hiring, with 152 active job postings in 2026, and its workforce is primarily concentrated in the United States. Revelio Labs data indicates that …

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside

Arrowhead Pharmaceuticals, Inc.'s stock 12-month price target has been increased from $104.7 to $105.4 by analysts, indicating a potential 23% upside from its July 27th closing price. The consensus rating from 14 analysts remains a "Buy," with a range of forecasts from $87 to …

Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Tuesday

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals has completed enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNAi therapeutic targeting homozygous familial hypercholesterolemia (HoFH). The study, which enrolled 70 patients, is expected to be completed in mid-2027, after which Arrowhead plans to seek regulatory …

Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial

Arrowhead Pharmaceuticals announced the completion of enrollment for its Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNA interference treatment for homozygous familial hypercholesterolemia (HoFH). While this is a significant milestone, the company's financial metrics reflect challenges in profitability and growth, with a …

Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients

Arrowhead Pharmaceuticals announced the completion of enrollment for its global Phase 3 YOSEMITE clinical trial of zodasiran, an investigational RNA interference therapeutic for homozygous familial hypercholesterolemia (HoFH). The study, which initially aimed for 60 participants but enrolled 70 due to strong interest, is expected …

5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%

(RTTNews) - "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." - Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing. The …

1,036,495 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Renaissance Technologies LLC

Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1

Arrowhead Pharmaceuticals Inc. (XETR:HDP1) reported a total revenue of €706.85 million last year, primarily driven by its RNA Interference Therapeutics segment. The United States was the leading geographical contributor, generating the entirety of this revenue. This marks a significant increase from €3.19 million in …